Literature DB >> 23045694

Transposon mutagenesis identifies genes that transform neural stem cells into glioma-initiating cells.

Hideto Koso1, Haruna Takeda, Christopher Chin Kuan Yew, Jerrold M Ward, Naoki Nariai, Kazuko Ueno, Masao Nagasaki, Sumiko Watanabe, Alistair G Rust, David J Adams, Neal G Copeland, Nancy A Jenkins.   

Abstract

Neural stem cells (NSCs) are considered to be the cell of origin of glioblastoma multiforme (GBM). However, the genetic alterations that transform NSCs into glioma-initiating cells remain elusive. Using a unique transposon mutagenesis strategy that mutagenizes NSCs in culture, followed by additional rounds of mutagenesis to generate tumors in vivo, we have identified genes and signaling pathways that can transform NSCs into glioma-initiating cells. Mobilization of Sleeping Beauty transposons in NSCs induced the immortalization of astroglial-like cells, which were then able to generate tumors with characteristics of the mesenchymal subtype of GBM on transplantation, consistent with a potential astroglial origin for mesenchymal GBM. Sequence analysis of transposon insertion sites from tumors and immortalized cells identified more than 200 frequently mutated genes, including human GBM-associated genes, such as Met and Nf1, and made it possible to discriminate between genes that function during astroglial immortalization vs. later stages of tumor development. We also functionally validated five GBM candidate genes using a previously undescribed high-throughput method. Finally, we show that even clonally related tumors derived from the same immortalized line have acquired distinct combinations of genetic alterations during tumor development, suggesting that tumor formation in this model system involves competition among genetically variant cells, which is similar to the Darwinian evolutionary processes now thought to generate many human cancers. This mutagenesis strategy is faster and simpler than conventional transposon screens and can potentially be applied to any tissue stem/progenitor cells that can be grown and differentiated in vitro.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23045694      PMCID: PMC3497753          DOI: 10.1073/pnas.1215899109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  56 in total

1.  Neurofibroma-associated growth factors activate a distinct signaling network to alter the function of neurofibromin-deficient endothelial cells.

Authors:  Amy M Munchhof; Fang Li; Hilary A White; Laura E Mead; Theresa R Krier; Amy Fenoglio; Xiaohong Li; Jin Yuan; Feng-Chun Yang; David A Ingram
Journal:  Hum Mol Genet       Date:  2006-04-28       Impact factor: 6.150

Review 2.  Stem cells, cancer, and cancer stem cells.

Authors:  T Reya; S J Morrison; M F Clarke; I L Weissman
Journal:  Nature       Date:  2001-11-01       Impact factor: 49.962

3.  Mutational inactivation of STAG2 causes aneuploidy in human cancer.

Authors:  David A Solomon; Taeyeon Kim; Laura A Diaz-Martinez; Joshlean Fair; Abdel G Elkahloun; Brent T Harris; Jeffrey A Toretsky; Steven A Rosenberg; Neerav Shukla; Marc Ladanyi; Yardena Samuels; C David James; Hongtao Yu; Jung-Sik Kim; Todd Waldman
Journal:  Science       Date:  2011-08-19       Impact factor: 47.728

4.  Large-scale analysis of the regulatory architecture of the mouse genome with a transposon-associated sensor.

Authors:  Sandra Ruf; Orsolya Symmons; Veli Vural Uslu; Dirk Dolle; Chloé Hot; Laurence Ettwiller; François Spitz
Journal:  Nat Genet       Date:  2011-03-20       Impact factor: 38.330

5.  Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.

Authors:  Kenneth P Olive; David A Tuveson; Zachary C Ruhe; Bob Yin; Nicholas A Willis; Roderick T Bronson; Denise Crowley; Tyler Jacks
Journal:  Cell       Date:  2004-12-17       Impact factor: 41.582

6.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Authors:  Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

7.  Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis.

Authors:  Robert M Bachoo; Elizabeth A Maher; Keith L Ligon; Norman E Sharpless; Suzanne S Chan; Mingjian James You; Yi Tang; Jessica DeFrances; Elizabeth Stover; Ralph Weissleder; David H Rowitch; David N Louis; Ronald A DePinho
Journal:  Cancer Cell       Date:  2002-04       Impact factor: 31.743

8.  Genetic variegation of clonal architecture and propagating cells in leukaemia.

Authors:  Kristina Anderson; Christoph Lutz; Frederik W van Delft; Caroline M Bateman; Yanping Guo; Susan M Colman; Helena Kempski; Anthony V Moorman; Ian Titley; John Swansbury; Lyndal Kearney; Tariq Enver; Mel Greaves
Journal:  Nature       Date:  2010-12-15       Impact factor: 49.962

9.  High-throughput semiquantitative analysis of insertional mutations in heterogeneous tumors.

Authors:  Marco J Koudijs; Christiaan Klijn; Louise van der Weyden; Jaap Kool; Jelle ten Hoeve; Daoud Sie; Pramudita R Prasetyanti; Eva Schut; Sjors Kas; Theodore Whipp; Edwin Cuppen; Lodewyk Wessels; David J Adams; Jos Jonkers
Journal:  Genome Res       Date:  2011-08-18       Impact factor: 9.043

10.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Authors: 
Journal:  Nature       Date:  2008-09-04       Impact factor: 49.962

View more
  33 in total

1.  Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma.

Authors:  Krishna P L Bhat; Veerakumar Balasubramaniyan; Brian Vaillant; Ravesanker Ezhilarasan; Howard Colman; Erik P Sulman; Kenneth Aldape; Karlijn Hummelink; Faith Hollingsworth; Khalida Wani; Lindsey Heathcock; Johanna D James; Lindsey D Goodman; Siobhan Conroy; Lihong Long; Nina Lelic; Suzhen Wang; Joy Gumin; Divya Raj; Yoshinori Kodama; Aditya Raghunathan; Adriana Olar; Kaushal Joshi; Christopher E Pelloski; Amy Heimberger; Se Hoon Kim; Daniel P Cahill; Ganesh Rao; Wilfred F A Den Dunnen; Hendrikus W G M Boddeke; Heidi S Phillips; Ichiro Nakano; Frederick F Lang
Journal:  Cancer Cell       Date:  2013-08-29       Impact factor: 31.743

Review 2.  Brain stem cells as the cell of origin in glioma.

Authors:  Aram S Modrek; N Sumru Bayin; Dimitris G Placantonakis
Journal:  World J Stem Cells       Date:  2014-01-26       Impact factor: 5.326

3.  Transposon mutagenesis identifies genes and cellular processes driving epithelial-mesenchymal transition in hepatocellular carcinoma.

Authors:  Takahiro Kodama; Justin Y Newberg; Michiko Kodama; Roberto Rangel; Kosuke Yoshihara; Jean C Tien; Pamela H Parsons; Hao Wu; Milton J Finegold; Neal G Copeland; Nancy A Jenkins
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-31       Impact factor: 11.205

4.  An Efficient In Vitro Transposition Method by a Transcriptionally Regulated Sleeping Beauty System Packaged into an Integration Defective Lentiviral Vector.

Authors:  Daniela Benati; Fabienne Cocchiarella; Alessandra Recchia
Journal:  J Vis Exp       Date:  2018-01-12       Impact factor: 1.355

5.  Transposon mediated integration of plasmid DNA into the subventricular zone of neonatal mice to generate novel models of glioblastoma.

Authors:  Anda-Alexandra Calinescu; Felipe Javier Núñez; Carl Koschmann; Bradley L Kolb; Pedro R Lowenstein; Maria G Castro
Journal:  J Vis Exp       Date:  2015-02-22       Impact factor: 1.355

Review 6.  Sleeping Beauty transposon insertional mutagenesis based mouse models for cancer gene discovery.

Authors:  Branden S Moriarity; David A Largaespada
Journal:  Curr Opin Genet Dev       Date:  2015-06-04       Impact factor: 5.578

Review 7.  Reprogramming strategies for the establishment of novel human cancer models.

Authors:  Ignacio Sancho-Martinez; Juan Carlos Izpisua Belmonte
Journal:  Cell Cycle       Date:  2016-06-17       Impact factor: 4.534

Review 8.  The La and related RNA-binding proteins (LARPs): structures, functions, and evolving perspectives.

Authors:  Richard J Maraia; Sandy Mattijssen; Isabel Cruz-Gallardo; Maria R Conte
Journal:  Wiley Interdiscip Rev RNA       Date:  2017-08-07       Impact factor: 9.957

Review 9.  Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge.

Authors:  Dominik Sturm; Sebastian Bender; David T W Jones; Peter Lichter; Jacques Grill; Oren Becher; Cynthia Hawkins; Jacek Majewski; Chris Jones; Joseph F Costello; Antonio Iavarone; Kenneth Aldape; Cameron W Brennan; Nada Jabado; Stefan M Pfister
Journal:  Nat Rev Cancer       Date:  2014-02       Impact factor: 60.716

Review 10.  Cancer gene discovery: exploiting insertional mutagenesis.

Authors:  Marco Ranzani; Stefano Annunziato; David J Adams; Eugenio Montini
Journal:  Mol Cancer Res       Date:  2013-08-08       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.